Tideglusib is really a GSK-3 inhibitor currently in stage II clinical studies for the treating Alzheimer disease and progressive supranuclear palsy. of Cys-199 by an Ala residue within the enzyme appears to raise the dissociation price although the medication retains its inhibitory activity with reduced potency and longer residence time. Furthermore tideglusib didn’t inhibit some… Continue reading Tideglusib is really a GSK-3 inhibitor currently in stage II clinical